Abstract
Studies were conducted to evaluate the use of a murine SLE-like disease for the discovery of novel drugs: This disease is the result of a chronic form of a graft vs host (GVH) reaction. Using prednisolone (Pr), cyclophosphamide (Cy), indomethacin (Indo), and the isoxazol derivative, HWA 486, we found that only Indo was ineffective in inhibiting the SLE symptoms. Interestingly, HWA 486, which did not display any immunosuppressive activity, restored the suppressed T-cell response to the same level as found in healthy mice. We feel that this murine model of SLE could be of value for discovering substances with novel antirheumatic, and/or immunomodulating activities.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Literature
E. Gleichmann, E. H. van Elven and J. P. W. van der Veen,A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell co-operation. Preferential formation of autoantibodies characteristic of SLE. Eur. J. Immunol.12, 152–159 (1982).
R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharm.7, 7–18 (1985).
R. Bartlett,Immunopharmacological profile of HWA 486, a novel isoxazol derivative. II. In vivo immunomodulating effects differ from those of Cyclophosphamide, Prednisolone, or Cyclosporin A. Int. J. Immunopharm.8, 199–204 (1986).
E. H. van Elven, J. Agterberg, S. Sadal and E. Gleichmann,Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex II. Autoantibodies deposited along the basement membrane of skin and their relationship to immune-complex glomerulonephritis. J. Immunol.126, 1684–1691 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Popovic, S., Bartlett, R.R. The use of the murine chronic graft Vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents and Actions 21, 284–286 (1987). https://doi.org/10.1007/BF01966492
Issue Date:
DOI: https://doi.org/10.1007/BF01966492